Platinum Partners
Newswire Biotechnology News
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
VANCOUVER, July 30 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its financial results for the second quarter ended June 30, 2010. "We are pleased to report continued quarter over quarter growth in
Fri, 30 Jul 2010 08:00:00 EDT
Oncolytics Biotech(R) Inc. Announces Second Quarter 2010 Results
CALGARY, July 29 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended June 30, 2010. "We have recently passed a number of key milestones in our clinical
Thu, 29 Jul 2010 07:30:00 EDT
OncoGenex to Webcast Second Quarter Financial Results on Thursday, August 5, 2010
BOTHELL, WA and VANCOUVER, July 29 /CNW/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's second quarter financial results will be released on Thursday, August 5, 2010, and that the Company will host a conference call and live webcast at 4:30 p.m. EDT that
Thu, 29 Jul 2010 06:00:00 EDT
Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
VANCOUVER, July 28 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) announced positive results from its phase I clinical trial of MultiStem(R), its allogeneic cell therapy product, administered to individuals following acute
Wed, 28 Jul 2010 16:23:00 EDT
Stuck on BAND-AID® Brand? Sing the Famous Jingle to Support Safe Kids Canada
BAND-AID® Brand mobile recording studio travels to community events this summer to encourage Canadians to have fun and sing the jingle for a great cause
Wed, 28 Jul 2010 12:33:00 EDT
Cyplasin Biomedical Ltd Secures $10 Million Equity Credit Line Financing
EDMONTON, July 27 /CNW/ - Cyplasin Biomedical (CPBM: OTCBB and XYI1:FRA) is a product-oriented, specialty pharmaceutical company focused on developing products for the multi-billion dollar hepatitis C virus (HCV) market. The Company is pleased to announce that it has secured US$10 Million in financing
Tue, 27 Jul 2010 08:15:00 EDT
Lab Research enters into preferred provider agreement with large Japanese pharma company
www.labresearch.com Toronto Stock Exchange Symbol: LRI Canadian and Hungarian sites to increase technical and scientific staff
Mon, 26 Jul 2010 07:00:00 EDT